The SONE signaling cascade, comprising the receptor tyrosine kinase and its downstream effector SONE‑A , has emerged as a driver of proliferative and survival pathways in a subset of aggressive solid tumors, notably triple‑negative breast cancer (TNBC) and certain sarcomas. Despite its clear oncogenic role, therapeutic exploitation of this axis has been hampered by the lack of highly selective small‑molecule modulators that spare closely related kinases. SONE‑296 , a novel orally bioavailable inhibitor discovered by [Company X] through a structure‑guided medicinal‑chemistry campaign, demonstrates sub‑nanomolar potency (IC₅₀ = 28 nM) against SONE‑R, > 1,000‑fold selectivity over the kinome, and robust tumor growth inhibition in multiple xenograft models (Figure 1). Early‑phase clinical testing has confirmed target engagement in patient biopsies and an encouraging safety profile, positioning SONE‑296 as a leading candidate to fill the therapeutic void in SONE‑driven malignancies.
is a production code for a Japanese Adult Video (JAV) released around : The video features Yuuka Murakami (also known as Yuka Murakami). SONE-296